Chapter

Progression of Parkinson’s Disease Revealed by Imaging Studies

David J. Brooks

in Dopamine Handbook

Published in print October 2009 | ISBN: 9780195373035
Published online February 2010 | e-ISBN: 9780199865543 | DOI: https://dx.doi.org/10.1093/acprof:oso/9780195373035.003.0031
Progression of Parkinson’s Disease Revealed by Imaging Studies

Show Summary Details

Preview

This chapter discusses imaging studies of Parkinson's disease (PD). Imaging dopaminergic function with positron emission tomography (PET) and single photon computed emission tomography (SPECT) or changes in the expression of a PD-related profile (PDRP) with 18F-fluorodeoxyglucose (FDG) PET currently remain the best biomarkers for monitoring disease progression. These measurements correlate significantly with clinical disability in PD and are able to detect preclinical dysfunction. However, the modalities cannot be regarded as surrogate markers as they do not correlate well with clinical outcome in practice, and may well be directly influenced by medication changes. While structural changes in PD substantia nigra can be detected with transcranial sonograpy (TCS), the associated hyperechogenicity does not appear to alter as patients clinically deteriorate. Volumetric magnetic resonance imaging (MRI) is valuable for detecting progressive brain atrophy in PD patients who developed later dementia, but currently is unable to detect nigral volume changes.

Keywords: Parkinson's disease; transcranial sonography; brain imaging; positron emission tomography; magnetic resonrance imaging

Chapter.  6056 words.  Illustrated.

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or purchase to access all content.